Interim trial results test added treatment for high-risk prostate cancer
Published by BriefDash · · Toronto
An international Phase 3 trial of 1,106 people found that adding darolutamide to androgen-deprivation treatment prolonged the time before very-high-risk prostate cancer spread, compared with placebo. McGill researcher Tamim Niazi co-chaired the study. These are interim conference results: follow-up is incomplete, overall-survival benefit is not yet established, and longer-term data are needed before the approach can be treated as a confirmed new standard. Bayer funded the study.
Why it matters
The trial could inform care for a high-risk group, but the unfinished follow-up and sponsor funding make the longer-term evidence essential.
Source dated October 26, 2026 · McGill University ↗
Independent factual brief. Original BriefDash illustration. Automated preparation and publication; editorial policy ↗
Suggest a correction ↗